
FORM PTO-1594 (17) REC 06-14-	2002 - IFFT U.S. DEPARTMENT OF COMMERCE
OMB Not 0651±001 + (4xp. 4/94) Tab settings □ □ □ ▼	-IEET U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office
Tab settings □ □ □ ▼	0793 Y Y
To the Honorable Commissioner of Pata 10212	2783 — V V V I rease record the attached original documents or copy thereof.
Name of conveying party(ies):	
LabOne, Inc. 10101 Renner Blvd. Lenexa, KS 66213 Individual(s) General Partnership Corporation-State Other Additional name(s) of conveying party(ies) attached? Yes No Nature of conveyance: Assignment Security Agreement Other Change of Name	2. Name and address of receiving party(ies) Name:IPMorgan Chase Bank Internal Address:
Execution Date: June 11, 2002	(Designations must be a separate document from assignment) Additional name(s) & address(es) attached? Yes No
Application number(s) or patent number(s):	
A. Trademark Application No.(s) SEE ATT	B. Trademark Registration No.(s)
Additional numbers att	ached?¾□ Yes □ No
Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and registrations involved:
Name: Penelope Agodoa	00.0
Internal Address: Federal Research Corporation	7. Total fee (37 CFR 3.41)\$ 890,50
	☐ Enclosed
	7.4 7.4
	☐ Authorized to be charged to deposit account
Street Address: 400 7th Street, N.W. Suite 101	8. Deposit account number:
City: Washington State: DC ZIP: 20004	
77/2002 GTON11 00000060 2361099	(Attach duplicate copy of this page if paying by deposit account)
C:481 40.00 DP DO NOT US C:482 850.00 PP	E THIS SPACE
Maha Hussain Name of Person Signing	June 12, 2002 Signature Date
	cover sheet, attachments, and document:
Mail documents to be recorded with a	required cover sheet information to:



Schedule 12 (A) Patents

Linker-Associated Immunoassay for Glyphosate		Patents Pending		Concentrations of Biological Analytes	sence of		Dried Blood Spot Samples	Method of Gluclose Stabilization and Analysis in			(GGT) in Liquid Blood and Dried Blood	Assay Method for Gamma Glutamyltransferase		Patent	
09/392,354		Application Nulliber	The state of the s		5,506,114			5,204,267		Number: 2,016,704)	(Canadian Patent	5,096,812		U.S. Patent No.	
Laboratories, Inc.	2				Laboratories, Inc.			Usporn Lahoratories, Inc.	2		Laporatories, inc.	_		Novola di	Record Owner
	0/8/99		Filing Date		1	4/9/96			4/20/93			9	3/17/92		Issue Date

Schedule 12 (B) Trademarks

					ı		
Mark	Filing/Registration Date	Status	Registration / / Application	Date for Next Action	Description	Comment	Owner
LabOne Net	6/27/00	Registered	2,361,099	6/27/05	Beginning of one year window within which to file section 8/15 affidavit		LabOne, Inc.
Superblind	10/24/00	Registered	2,397,368	10/24/05	Beginning of one year window within which to file section 8/15 affidavit		LabOne, Inc.
CaseOne	7/10/01	Registered	2,467,422	7/10/06	Beginning of one year window within which to file section 8/15 affidavit		LabOne, Inc.
Test Tube and Beaker Logo with HORL	8/22/95	Registered	1,913,943		To be Abandoned.		LabOne, Inc.
nd	8/15/00	Registered	2,377,270	8/15/05	Beginning of one year window within which to file section 8/15 affidavit		LabOne, Inc.
ExamOne	5/29/01	Registered	2,454835	5/29/06	Beginning of one year window within which to file section 8/15 affidavit		LabOne, Inc.
SBSI	1/6/00	Registered	2,535,515	2/8/07	Beginning of one year window within which to file section 8/15 affidavit		SBSI
SBSI	1/5/00	Intent to Use Application	75/888390	6/4/02	File SOU or 1st extension		SBSI
SBSI and Design	Filed 1/6/00	Registered	2,539101	2/19/07	Beginning of one year window within which to file section 8/15 affidavit		SBSI
SBSI and Design	1/6/00	Intent to Use Application	75/888391	5/2/02	Expect Notice of Publication		SBSI
Home Office Reference Laboratory	5/14/91	Registered	1,644,723		To be Abandoned.		LabOne, Inc.

Inside Look 3	Doculink 1	Intellichoice 6.	Star System 5			ed)	Insight and Design 5	CPU to CPU	Express Results 2000 2	Lab Card 1:	PC/Desktop Express 8.	LabOne 5	esign	Lab One Page 1.	HORL 6	Head Office Reference 5	Mark
3/2/99	11/13/01	6/27/00	5/7/91			11/23/01	5/22/90	12/19/99	2/3/98	12/23/97	8/12/97	5/13/97	4/29/97	1/7/97	6/18/91	16/82/2	Filing/Registration Date
Registered	Registered	Registered	Renewed	0	Pending	Pending	Cancelled	Registered	Registered	Registered	Registered	Registered	Registered	Registered	Registered	Registered	Status
}	2,507,480	2,363,290	1,643,834			3)	1,597,391	1,572,666	2,133,881	2,124,087	2,087,497	2,061,737		2,029,145	1,648,462	1,646,440	Registration / / Application #
3/2/2004	11/13/2006	6/27/2005	5/7/2011			8/12/02		12/19/99	2/3/03	12/23/02	8/12/02	5/13/02 v	2	1/7/02			Date for Next Action
Beginning of one year section 8/15 window.	Beginning of one year section 8/15 window.	8/15 window.	File for renewal of registration		Respond to Office Action	Respond to Office Action	To be Abandoned.	File for renewal of registration	Beginning of one year section 8/15 window	Beginning of one year window within which to file section 8/15 affidavit	Beginning of one year window within which to file section 8/15 affidavit	Beginning of one year window within which to file section 8/15 affidavit	Beginning of one year window within which to file section 8/15 affidavit	To be Abandoned.	To be Abandoned.	To be Abandoned.	Description
Files received from Stitt & Paul Hastings.	File received from Stitt.	File received from Stitt.	Hastings.	Files received from Stitt & Paul													Comment
Osborn Group, Inc.	Laboratories, Inc.	Laboratories, Inc.	Osborn Group, Inc.		LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabOne, Inc.	LabUne, Inc.	LabOne, Inc.	Owner

Schedule 12 (C) Copyrights

Laboratory Bulletin 88-01 Laboratory Bulletin 88-02 Laboratory Bulletin 88-03 TX 2-436-943 TX 2-436-943 TX 2-436-943 TX 2-436-941 TX 2-436-940 TX 2-436-940 TX 2-436-940 TX 2-436-940 TX 2-436-940 TX 2-436-938 TX 2-559-445 TX 2-559-445 Laboratory Bulletin 89-02 TX 2-559-446 Laboratory Bulletin 89-03 TX 2-559-444 Laboratory Bulletin 89-05 TX 2-570-689 Laboratory Bulletin 89-09 TX 2-637-184 Laboratory Bulletin 89-11 TX 2-637-184 Laboratory Bulletin 89-13 TX 2-684-524 Laboratory Bulletin 89-14 TX 2-684-524 Laboratory Bulletin 89-15 TX 2-684-524 Laboratory Bulletin 89-16 TX 2-726-997

9, 110	2,000			
6/1/94	6/30/94	TX 3-836-004	Laboratory Bulletin 94-02	Profile Unice Reference Laboratory
2/10/94	2/25/94	TX 3-818-818	Laboratory Bulletin 94-01	Home Office Reference Laboratory
3/28/91	4/8/91	TX 3-041-947	Insight Vol. 5	Home Office Reference Laboratory
12/28/90	1/8/91	TX 2-986-678	Insight Vol. 4	Home Office Potential Laboratory
9/1/90	10/10/90	TX 2-918-262	Insight Vol. 4	Home Office Reference Laboratory
6/8/90	6/28/90	TX 2-877-033	Insight Vol. 4	Home Office Reference Laboratory
12/12/89	12/27/89	TX 2-712-211	Insight Vol. 3	Home Office Reference Laboratory
7/15/89	8/7/89	TX 2-625-072	Insight Vol. 3	Home Office Reference Laboratory
3/31/89	5/5/89	TX 2-545-402	Insight Vol. 3	Home Office Reference Laboratory
10/30/88	3/28/89	TX 2-519-705	Insight Vol. 2	Home Office Reference Laboratory
10/10/89	1/16/90	TX 2-720-003	Insight Vol. 3	Home Office Peferance Laboratory
12/30/88	5/5/89	TX 2-565-897	Insight Vol. 2	Home Office Reference Laboratory
4/19/88	12/5/88	TX 2-463-705	1987Annual Report	Home Office Reference Laboratory
7/7/94	8/4/94	TX 3-894-264	Laboratory Bulletin 94-03	Home Office Peferson Laboratory
6/1/94	6/30/94	TX 3-836-004	Laboratory Bulletin 94-02	Home Office Reference Laboratory
2/10/94	2/25/94	TX 3-818-818	Laboratory Bulletin 94-01	Home Office Reference Laboratory
12/6/93	12/15/93	TX 3-681-344	Laboratory Bulletin 93-14	Home Office Reference Laboratory
10/27/93	11/12/93	TX 3-686-979	Laboratory Bulletin 93-13	Home Office Reference Laboratory
10/27/93	11/12/93	TX 3-686-980	Laboratory Bulletin 93-12	Home Office Reference Laboratory
9/24/93	10/8/93	TX 3-648-829	Laboratory Bulletin 93-11	Home Office Reference Laboratory
9/24/93	10/8/93	TX 3-648-830	Laboratory Bulletin 93-10	Home Office Reference Laboratory
7/23/93	8/3/93	TX 3-621-500	Laboratory Bulletin 93-09	Home Office Reference Laboratory
6/2/93	6/11/93	TX 3-371-519	Laboratory Bulletin 93-08	Home Office Reference Laboratory
12/30/92	1/11/93	TX 3-618-022	Laboratory Bulletin 92-04	Home Office Reference Laboratory
4/19/93	4/26/93	TX 3-532-407	Laboratory Bulletin 93-07	Home Office Reference Laboratory
3/10/93	3/19/93	TX 3-494-345	Laboratory Bulletin 93-06	Home Office Reference Laboratory
2/22/93	3/8/93	TX 3-524-931	Laboratory Bulletin 93-05	Home Unice Reference Laboratory
2/3/93	2/16/93	TX 3-481-084	Laboratory Bulletin 93-04	Hornice Reference Laboratory
2/3/93	2/16/93	TX 3-481-085	Laboratory Bulletin 93-03	House Reference Laboratory
1/20/93	2/4/93	TX 3-478-192	Laboratory Bulletin 93-02	Homo Office Reference Laboratory
1/20/93	2/4/93	TX 3-478-191	Laboratory Bulletin 93-01	Homo Office Reference Laboratory
8/5/92	9/24/92	TX 3-399-533	Laboratory Bulletin 92-03	Home Ciffice Reference Laboratory
4/17/92	7/8/92	TX 3-373-428	Laboratory Bulletin 92-02	Horrie Office Reference Laboratory
3/25/92	7/8/92	TX 3-382-624	Laboratory Bulletin 92-01	Page 266 Reference Laboratory
12/30/91	2/10/92	TX 3-250-264	Laboratory Bulletin 91-09	Home Office Reference Laboratory
				Long Off

Technology, Techno	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-04 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 98-05 Laboratory Bulletin 98-05 Laboratory Bulletin 98-05 Laboratory Bulletin 98-05 Laboratory Bulletin 99-05 TX Laboratory Bulletin 90-08 TX TX Laboratory Bulletin 97-02 TX Laboratory Bulletin 98-05 TX Laboratory Bulletin 98-05 TX TX Laboratory Bulletin 98-05 TX Laboratory Bulletin 98-05 TX Laboratory Bulletin 98-05 TX TX Laboratory Bulletin 98-05 TX TX TX TX Laboratory Bulletin 98-05 TX	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1997 Insight Vol. 11, Spril 1997 Insight Nol. 11, Spril 1999 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology, Spring 1999 Insight Into Information Technology, Fall 1998 Insight Into Information Technology, Fall 1998 Urine HIV-1, Antibody Screening Vurine HIV-1, Antibody Screening Vurine Home Office Reference Laboratory, Inc., a Closer Look Home Office Reference Laboratory Manual	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulleti	4
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-04 Laboratory Bulletin 96-01 TX Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 9 Insight Vol. 10, Spring 1996 Insight Vol. 11, Sprill 1997 Insight Vol. 11, Sprill 1997 Insight, Fall 1998 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology, Insight Into Information Technology, Spring 1997 Insight Into Information Technology, Insight	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 96-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Sprill 1997 Insight Vol. 11, Sprill 1997 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology, Spring 1999 Insight Into Information Technology, Spring 1997 Insight Into Information Technology, Spring 1999 Insight Into Information Technology, Fall 1998 Urine HIV-1, Antibody Screening Vurine Hore Closer Look Inc. a Closer Look	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-07 Laboratory Bulletin 96-07 Laboratory Bulletin 96-07 Laboratory Bulletin 97-02 Lipsight Vol. 10, Spring 1996 Lipsight Vol. 11, Spring 1996 Lipsight Vol. 11, Spring 1997 Lipsight, Spring 1999 Linsight, Spring 1999 Linsight Into Information Technology, Fall Insight Services-a HORL trademark Client Services-a HORL trademark	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulleti	-
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 97-02 Laboratory Bulletin 97-05 Linsight Vol. 10, Spring 1996 Linsight Vol. 11, Spring 1996 Linsight Vol. 11, Spring 1997 Linsight, Spring 1999 Linsight Into Information Technology, Fall 1998	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-05 Laboratory Bulletin 97-07 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulleti	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-07 Laboratory Bulletin 96-07 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-02 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-02 Laboratory Bulleti	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996 Insight Vol. 11, Spril 1997 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology, Spring 1999 Insight Into Information Technology, Fall Insight Insig	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996 Insight Vol. 11, Spril 1997 Insight, Fall 1998 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology, Spring 1999 Insight Into Information Technology, Spring 1997	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-05 Laboratory Bulletin 96-05 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 96-02 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 96-05 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 97-01 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulleti	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 98-05 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996 Insight Vol. 11, Spril 1997 Insight, Fall 1998 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight Into Information Technology Spring 1999 Spring 1999	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 90-05 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1997 Insight, Spring 1999 Insight Into Information Technology. Spring 1999 Spring 1999	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Sprill 1996 Insight, Spring 1999	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 98-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1997 Insight, Spring 1999	1
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight, Spring 1998 Insight, Spring 1999	Laboratory Bulletin 94-04 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-07 Laboratory Bulletin 97-07 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 98-05 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996 Insight Vol. 11, Spril 1997 Insight, Spring 1999 Insight Vol. 10, Fall 1996 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight, Fall 1998 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999 Insight, Spring 1999	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight, Fall 1998 Insight, Fall 1998 Insight, Spring 1999	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1997 Insight, Fall 1998 Insight, Fall 1998 Insight, Spring 1998 Insight, Spring 1999	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight Vol. 11, Spril 1997 Insight, Fall 1998	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996 Insight Vol. 11, Spril 1997 Insight, Fall 1998	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 9 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1996 Insight Vol. 11, Spril 1997	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 11, Spril 1997	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 10, Spring 1996 Insight Vol. 10, Fall 1996	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 9 Insight Vol. 10, Spring 1996	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 9 Insight Vol. 10, Spring 1996	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8 Insight Vol. 9	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-05 Insight Vol. 8 Insight Vol. 9	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05 Insight Vol. 8	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Insight Vol. 8	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02 Laboratory Bulletin 96-05	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 97-02 Laboratory Bulletin 97-02	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02 Laboratory Bulletin 97-01	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01 Laboratory Bulletin 96-02	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No. Laboratory Bulletin 96-01	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No.	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05 Laboratory Bulletin Vol. 95, No.	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04 Laboratory Bulletin 94-05	
Laboratory Bulletin 94-03 Laboratory Bulletin 94-04	Laboratory Bulletin 94-03 Laboratory Bulletin 94-04	
Laboratory Bulletin 94-03	Laboratory Bulletin 94-03	

101101	CONCENT	TX 2-686-110	Laboratory Bulletin 89-12	Home Office Reference Laboratory
10/10/89	10/25/80	17.000 140	to Ennance Kisk Selection	Home Unice Reference Laboratory
11/15/89	11/27/89	TY 2-684-163	Laboratory Testing Options: Designed	
11/1/89	11/13/89	TX 2-683-475	Prostate-specific Antigen (PSA) Testing, Tumor Marker for Prostate Cancer	Home Office Reference Laboratory
1 11 116	11/10/08	TX 2-683-4/4	Fructosamine	Home Office Reference Laboratory
11/1/89	44/42/90	TX 2-658-732	Laboratory Bulletin 89-07	Home Office Reference Laboratory
0/8/80	8/25/89	TX 2-639-022	Laboratory Bulletin 89-10	Home Office Reference Laboratory
4/12/89	6/23/89	TX 2-611-806	Testing New Opportunities for Group Insurance	Home Office Reference Laboratory
69/77/6	6/23/89	TX 2-602-806	Laboratory Bulletin 89-06	Home Office Reference Laboratory
8/19/88	10/24/88	TX 2-468-708	Head Office Reference Laboratory Bulletin	Home Office Reference Laboratory
#/#/OO	09/0/71	TX 2-463-309	An Inside Perspective	Home Office Reference Laboratory
8/7/7	7/2/190	PA 454-24/	II (videocassette)	Home Office Reference Laboratory
2/8/90	27400	· · · · · · · · · · · · · · · · · · ·	e Reference Laboratory Il Instruction: Segments I &	
01200	7/10/93	TX 3-619-513		Home Office Reference Laboratory
E/20/0:			umentation,	
4/20/93	4/29/93	TX 3-540-659	Electronic Billing Technical Documentation, Version 2.0	Home Office Reference Laboratory
	10/17/02	1X 3-468-280		Home Office Reference Laboratory
3/25/92	7/8/92	TX 3-376-840	Ethanol Intake Marker Reference Guide	Home Office Reference Laboratory
10/1/91	12/6/91	TX 3-209-288	Version 4.0	Home Office Reference Laboratory
2/27/91	2/27/91	TX 3-161-348	ons About creening tin 91-02	Home Office Reference Laboratory
16/1/2/9	9/9/91	TX 3-148-325		Home Office Reference Laboratory
7/15/91	8/1/91	TX 3-134-235		Home Office Reference Laboratory
3/19/91	4/8/91	TX 3-063-149		Home Office Reference aboratory
2/11/91	2/28/91	TX 3-039-974	New Blood Kit and Postal Rates:	Home Office Reference I shorston

12/4/97 3/1/97 8/20/99 5/15/99 8/23/99 5/15/99 10/12/99 5/29/99 10/12/99 5/29/99 10/12/99 5/29/99 10/7/91 9/23/91 10/7/92 1/28/92 7/8/92 6/30/92 10/14/92 9/30/92 1/11/93 1/21/9/92 4/26/93 4/19/93	TX 3-410-747 TX 3-467-765	Insight, Vol. 7	Home Unice Reference Laboratory
	TX 3-410-747	1	
	TX 3-410-747	Hisight, vol. o	Tolle Office Releiging Laboratory
		Insight Vol 6	Home Office Reference I aboratory
	TX 3-376-95/	Insight, Vol. 6	Home Office Reference Laboratory
	1X 3-234-111	Insight, Vol. 6	Home Office Reference Laboratory
	TX 3-100-221	Insight, Vol. 5	Home Office Reference Laboratory
	TV 2 100 227	Insight, Vol. 5	Home Office Reference Laboratory
	TV E 451.785	Lab Card	LabOne, Inc.
	TV 5 002-274	Before They Draw Blood Draw your	
cn.	TX 5-092-273	Having a Lab Card as as Good as Money in Your Wallet	LabOne, Inc.
CD.	TX 5-021-594	Outpatient Laboratory Testing	LabOne, Inc.
	TX 5-019-473	Card	LabOne, Inc.
		Have a Health Wallet-Use Your Lab	רמה כווס, וווס.
	TX 4-604-822	LabOne NET-The Connection to Your	lahOne Inc
12/5/97 3/10/97	TX 4-584-950	LabOne Net LabLink User's Guide: Version 1.1-002	LabOne, Inc.
9/24/90 8/14/90	TX 2-925-457	Laboratory Bulletin 90-07; Cambridge Recombigen Assay	Home Office Reference Laboratory
8/6/90 7/11/90	TX 2-897-126	Format-Option Second Page Report	Home Office Reference Laboratory
	X 2-831-111	Specimen Tube Identification	Home Office Reference Laboratory
10/2/89 9/8/89		Laboratory Bulletin 89-07; Exhibit A, Urine Container Status; Exhibit B, HIV	
	X 2-834-873	HORL's Value-Added Services	Home Office Reference Laboratory
5/21/90 5/4/90 5/22/90 4/26/90	TX 2-833-741	Problem	Home Office Reference Laboratory
	V 7-00-	Laboratory Bulletin 90-04	Home Office Reference Laboratory
5/21/90 5/1/90	1X 2-101-240		Home Office Reference Laboratory
11/20/89 3/15/90 2/21/90	TX 2-701-063	3-Positive 18	Home Office Reference Laboratory
11/13/89 11/1/89	TX 2-692-146	<u> </u>	Home Office Reference Laboratory

				L	
		1X 3-143-030	Vol. 8	Insight, Vol. 8	Home Office Reference Laboratory
1/25/94	2/4/94	7/5 908	Vol. 7	Insight, Vol.	Home Office Reference Laboratory
\ \ \ &	2/7/94	TV 2 753.547	V0I. /	insignt, Voi.	Home Office Reference Laboratory
6/30/93	7/13/93	TX 3-599-519	7.1.7		

SECURITY AGREEMENT dated as of June 11, 2002, among LABONE, INC., a Missouri corporation (the "Company"), each Subsidiary of the Company listed on Schedule I hereto or becoming a party hereto as provided in Section 7.15 (the "Subsidiary Grantors"; the Company and the Subsidiary Grantors being referred to collectively as the "Grantors") and JPMORGAN CHASE BANK, a New York banking corporation, as collateral agent (in such capacity, the "Collateral Agent"), for the Secured Parties (as defined in the Credit Agreement referred to below).

Reference is made to (a) the Credit Agreement dated as of June 11, 2002 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Company, the lenders from time to time party thereto (the "Lenders"), the issuing banks from time to time thereto (the "Issuing Banks"), and JPMorgan Chase Bank, as administrative agent (in such capacity, the "Administrative Agent") and Collateral Agent, (b) the Guarantee Agreement dated as of June 11, 2002, among certain subsidiaries of the Company and the Collateral Agent (as amended, supplemented or otherwise modified from time to time, the "Subsidiary Guarantee Agreement") and (c) the other Loan Documents referred to in the Credit Agreement. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Credit Agreement.

The Lenders and Issuing Banks have agreed to extend credit to the Company pursuant to, and upon the terms and subject to the conditions specified in, the Credit Agreement. The obligations of the Lenders or the Issuing Banks to extend such credit are conditioned upon, among other things, the execution and delivery by the Grantors of an agreement in the form hereof to secure the Obligations.

Accordingly, the Grantors and the Collateral Agent, on behalf of itself and each Secured Party (and each of their respective successors or assigns), hereby agree as follows:

ARTICLE I

Definitions

SECTION 1.01. <u>Definition of Terms Used Herein.</u> (a) Unless the context otherwise requires, all capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Credit Agreement and all references to the Uniform Commercial Code shall mean the Uniform Commercial Code in effect in the State of New York as of the date hereof.

(b) As used herein, the following terms shall have the following meanings:

"Account Debtor" shall mean any person who is or who may become obligated to any Grantor under, with respect to or on account of an Account.

"Accounts" shall mean any and all right, title and interest of any Grantor to payment of a monetary obligation (i) for property that has been or is to be sold, leased, licensed, assigned or otherwise disposed of, (ii) for services rendered or to be rendered (including, without limitation, any healthcare insurance receivables in relation thereto), (iii) for a policy of insurance issued or to be issued, (iv) for a secondary obligation incurred or to be incurred, (v) for energy provided or to be provided, (vi) for the use or hire of a vessel under charter or (vii) arising out of the use of a credit or charge card or information contained on or for use with the card, including any such right evidenced by Chattel Paper, whether due or to become due, whether or not it has

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

been earned by performance, and whether now or hereafter acquired or arising in the future, including Accounts Receivable from Affiliates of the Grantors.

"Accounts Receivable" shall mean all Accounts and all right, title and interest in any returned goods, together with all rights, titles, securities and guarantees with respect thereto, including any rights to stoppage in transit, replevin, reclamation and resales, and all related security interests, liens and pledges, whether voluntary or involuntary, in each case whether now existing or owned or hereafter arising or acquired.

"Chattel Paper" shall mean (a) a record or records which evidence both a monetary obligation and a security interest in or a lease of specific goods and (b) all other property now or hereafter constituting "chattel paper" under the Uniform Commercial Code as in effect in the State of New York or its equivalent in other jurisdictions, in each case that are now or hereafter owned by Grantor.

"Collateral" shall mean all (a) Accounts Receivable, (b) Chattel Paper, (c) Documents, (d) Equipment, (e) Equity Interests, (f) General Intangibles, (g) Inventory, (h) cash and deposit accounts, (i) Indebtedness, (j) Intellectual Property, (k) Investment Property, (l) letter of credit rights, (m) other assets of any kind or nature in which a security interest can be created under the Uniform Commercial Code and (n) Proceeds; provided that "Collateral" shall not include any Excluded Asset.

"Commodity Account" shall mean an account maintained by a Commodity Intermediary in which a Commodity Contract is carried for a Commodity Customer.

"Commodity Contract" shall mean a commodity futures contract, an option on a commodity futures contract, a commodity option or any other contract that, in each case, is (a) traded on or subject to the rules of a board of trade that has been designated as a contract market for such a contract pursuant to the federal commodities laws or (b) traded on a foreign commodity board of trade, exchange or market, and is carried on the books of a Commodity Intermediary for a Commodity Customer.

"Commodity Customer" shall mean a person for whom a Commodity Intermediary carries a Commodity Contract on its books.

"Commodity Intermediary" shall mean (a) a person who is registered as a futures commission merchant under the federal commodities laws or (b) a person who in the ordinary course of its business provides clearance or settlement services for a board of trade that has been designated as a contract market pursuant to federal commodities laws.

"Copyright License" shall mean any written agreement, now or hereafter in effect, granting any right to any third party under any copyright now or hereafter owned by any Grantor or that such Grantor otherwise has the right to license, or granting any right to any Grantor under any copyright now or hereafter owned by any third party, and all rights of such Grantor under any such agreement.

"Copyrights" shall mean all of the following now owned or hereafter acquired by any Grantor: (a) all copyright rights in any work subject to the copyright laws of the United States or any other country, whether as author, assignee, transferee or otherwise, and (b) all registrations and applications for registration of any such copyright in the United States or any other country, including registrations, recordings, supplemental registrations and pending applications for registration in the United States Copyright Office or any similar offices in any other country.

"Credit Agreement" shall have the meaning assigned to such term in the preliminary statement of this Agreement.

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

"<u>Documents</u>" shall mean all instruments, files, records, ledger sheets and documents covering or relating to any of the Collateral.

"Entitlement Holder" shall mean a person identified in the records of a Securities Intermediary as the person having a Security Entitlement against the Securities Intermediary. If a person acquires a Security Entitlement by virtue of Section 8-501(b)(2) or (3) of the Uniform Commercial Code, such person is the Entitlement Holder.

"Equipment" shall mean all equipment, furniture and furnishings and all tangible personal property similar to any of the foregoing, including tools, parts and supplies of every kind and description, and all improvements, accessions or appurtenances thereto, that are now or hereafter owned by any Grantor. The term Equipment shall include Fixtures.

"Equity Interests" shall mean shares of capital stock, partnership interests, membership interests in a limited liability company, beneficial interests in a trust or other equity ownership interests in a Person of whatever nature and rights, warrants or options to acquire any of the foregoing.

"Excluded Asset" means any asset that is (a) subject to a Lien permitted pursuant to Section 6.02(c), (e), (h) or (i) of the Credit Agreement to the extent the agreement or applicable law creating such Lien or the Indebtedness secured by such Lien prohibits the granting of a second Lien on such asset or the granting of a second Lien on such asset would cause the foreclosure or forfeiture of such asset; provided that upon the termination of all prior Liens on any of the foregoing assets, such asset shall cease to be an Excluded Asset or (b) excluded from the Indebtedness required to be pledged under the Pledge Agreement by clause (b)(ii) of the definition of Collateral and Guarantee Requirement set forth in the Credit Agreement.

"Financial Asset" shall mean (a) a Security, (b) an obligation of a person or a share, participation or other interest in a person or in property or an enterprise of a person, which is, or is of a type, dealt with in or traded on financial markets, or which is recognized in any area in which it is issued or dealt in as a medium for investment or (c) any property that is held by a Securities Intermediary for another person in a Securities Account if the Securities Intermediary has expressly agreed with the other person that the property is to be treated as a Financial Asset under Article 8 of the Uniform Commercial Code. As the context requires, the term Financial Asset shall mean either the interest itself or the means by which a person's claim to it is evidenced, including a certificated or uncertificated Security, a certificate representing a Security or a Security Entitlement.

"<u>Fixtures</u>" shall mean all items of Equipment, whether now owned or hereafter acquired, of any Grantor that become so related to particular real estate that an interest in them arises under any real estate law applicable thereto.

"General Intangibles" shall mean all choses in action and causes of action and all other assignable intangible personal property of any Grantor of every kind and nature (other than Accounts Receivable) now owned or hereafter acquired by any Grantor, including corporate or other business records, indemnification claims, contract rights (including (a) rights under leases, whether entered into as lessor or lessee (but excluding real estate leases), (b) rights under any Hedging Agreement, (c) any intercompany payment obligations not evidenced by any instrument and (d) other agreements), goodwill, registrations, franchises, tax refund claims and any letter of credit, guarantee, claim, security interest or other security held by or granted to any Grantor to secure payment by an Account Debtor of any of the Accounts Receivable.

"Indebtedness" has the meaning assigned to such term in the Credit Agreement.

"Intellectual Property" shall mean all intangible, intellectual and similar property of any Grantor of every kind and nature now owned or hereafter acquired by any Grantor,

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

including inventions, designs, Patents, Copyrights, Licenses, Trademarks, trade secrets, confidential or proprietary technical and business information, know-how, show-how or other data or information, software and databases and all embodiments or fixations thereof and related documentation, registrations and franchises, and all additions, improvements and accessions to, and books and records describing or used in connection with, any of the foregoing.

"Inventory" shall mean all goods of any Grantor, whether now owned or hereafter acquired, held for sale or lease (other than goods of customers held for consignment), or furnished or to be furnished by any Grantor under contracts of service or consumed in any Grantor's business, including raw materials, intermediates, work in process, packaging materials, finished goods, semi-finished inventory, scrap inventory, manufacturing supplies and spare parts, and all such goods that have been returned to or repossessed by or on behalf of any Grantor.

"Investment Property" shall mean all Securities (whether certificated or uncertificated), Security Entitlements, Securities Accounts, Commodity Contracts and Commodity Accounts of any Grantor, whether now owned or hereafter acquired by any Grantor.

"<u>License</u>" shall mean any Patent License, Trademark License, Copyright License or other license or sublicense to which any Grantor is a party, other than those licenses or license agreements which by their terms prohibit (or as to which applicable law prohibits) assignment or a grant of a security interest by such Grantor.

"Obligations" shall mean (a) the due and punctual payment of (i) the principal of, and premium, if any, and interest (including interest accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding) on the Loans, when and as due, whether at maturity, by acceleration, upon one or more dates set for prepayment or otherwise, (ii) each payment required to be made under the Credit Agreement in respect of any Letter of Credit, when and as due, including payments in respect of reimbursement of drawings or disbursements, interest thereon and obligations to provide cash collateral and (iii) all other monetary obligations, including fees, costs, expenses and indemnities, whether primary, secondary, direct, contingent, fixed or otherwise (including monetary obligations incurred during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), of the Loan Parties to the Secured Parties under the Credit Agreement and the other Loan Documents, (b) the due and punctual performance of all covenants, agreements, obligations and liabilities of the Loan Parties, monetary or otherwise, under or pursuant to this Agreement and the other Loan Documents and (c) the due and punctual payment of all obligations of the Company or any Subsidiary under each Hedging Agreement entered into (i) prior to the date hereof with any counterparty that is a Lender (or an Affiliate thereof) on the date hereof or (ii) on or after the date hereof with any counterparty that is a Lender (or an Affiliate thereof) at the time such Hedging Agreement is entered into.

"Patent License" shall mean any written agreement, now or hereafter in effect, granting to any third party any right to make, use or sell any invention on which a patent, now or hereafter owned by any Grantor or that any Grantor otherwise has the right to license, is in existence, or granting to any Grantor any right to make, use or sell any invention on which a patent, now or hereafter owned by any third party, is in existence, and all rights of any Grantor under any such agreement.

"Patents" shall mean all of the following now owned or hereafter acquired by any Grantor: (a) all letters patent of the United States or any other country, all registrations and recordings thereof and all applications for letters patent of the United States or any other country, including registrations, recordings and pending applications in the United States Patent and Trademark Office or any similar offices in any other country and (b) all reissues, continuations, divisions, continuations-in-part, renewals or extensions thereof and the inventions disclosed or

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

claimed therein, including the right to make, use and/or sell the inventions disclosed or claimed therein.

"Perfection Certificate" shall mean a certificate substantially in the form of Exhibit G to the Credit Agreement or any other form approved by the Collateral Agent, completed and supplemented with the schedules and attachments contemplated thereby, and duly executed by a Financial Officer and the chief legal officer of the Company.

"Proceeds" shall mean any consideration received from the sale, exchange, license, lease or other disposition of any asset or property that constitutes Collateral, any value received as a consequence of the possession of any Collateral and any payment received from any insurer or other Person or entity as a result of the destruction, loss, theft, damage or other involuntary conversion of whatever nature of any asset or property which constitutes Collateral and shall include (a) any claim of any Grantor against any third party for (and the right to sue and recover for and the rights to damages or profits due or accrued arising out of or in connection with) (i) past, present or future infringement of any Patent now or hereafter owned by any Grantor or licensed to any Grantor under a Patent License, (ii) past, present or future infringement or dilution of any Trademark now or hereafter owned by any Grantor or licensed under a Trademark License or injury to the goodwill associated with or symbolized by any Trademark now or hereafter owned by any Grantor, (iii) past, present or future infringement of any Copyright now or hereafter owned by any Grantor or licensed to a Grantor under a Copyright License and (iv) past, present or future breach of any License and (b) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral.

"Secured Parties" shall mean the Administrative Agent, the Collateral Agent, each Lender, each Issuing Bank, each other Person to whom any of the Obligations is owed and the successors and assigns of each of the foregoing.

"Securities" shall mean any obligations of an issuer or any shares, participations or other interests in an issuer or in property or an enterprise of an issuer which (a) are represented by a certificate representing a security in bearer or registered form, or the transfer of which may be registered upon books maintained for that purpose by or on behalf of the issuer, (b) are one of a class or series or by its terms is divisible into a class or series of shares, participations, interests or obligations and (c)(i) are, or are of a type, dealt with or traded on securities exchanges or securities markets or (ii) are a medium for investment and by their terms expressly provide that they are a security governed by Article 8 of the Uniform Commercial Code (other than as expressly excluded by Section 8-103(c), (e), and (f) of such Article).

"Securities Account" shall mean an account to which a Financial Asset is or may be credited in accordance with an agreement under which the person maintaining the account undertakes to treat the person for whom the account is maintained as entitled to exercise rights that comprise the Financial Asset.

"Security Entitlements" shall mean the rights and property interests of an Entitlement Holder with respect to a Financial Asset.

"Security Interest" shall have the meaning assigned to such term in Section 2.01.

"Securities Intermediary" shall mean (a) a clearing corporation or (b) a person, including a bank or broker, that in the ordinary course of its business maintains securities accounts for others and is acting in that capacity.

"Trademark License" shall mean any written agreement, now or hereafter in effect, granting to any third party any right to use any trademark now or hereafter owned by any Grantor or that any Grantor otherwise has the right to license, or granting to any Grantor any right to use

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

any trademark now or hereafter owned by any third party, and all rights of any Grantor under any such agreement.

"Trademarks" shall mean all of the following now owned or hereafter acquired by any Grantor: (a) all trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, logos, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all registration applications filed in connection therewith, including registrations and registration applications in the United States Patent and Trademark Office, any State of the United States or any similar offices in any other country or any political subdivision thereof, and all extensions or renewals thereof, (b) all goodwill associated therewith or symbolized thereby and (c) all other assets, rights and interests that uniquely reflect or embody such goodwill.

SECTION 1.02. <u>Rules of Interpretation</u>. The rules of interpretation specified in Sections 1.03 and 1.04 of the Credit Agreement shall be applicable to this Agreement.

ARTICLE II

Security Interest

SECTION 2.01. Security Interest. (a) As security for the payment or performance, as the case may be, in full of the Obligations and any extensions, renewals, modifications or refinancings of the Obligations, each Grantor hereby mortgages and pledges to the Collateral Agent, its successors and assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and assigns, for the ratable benefit of the Secured Parties, a security interest in, all such Grantor's right, title and interest in, to and under the Collateral (the "Security Interest"). Without limiting the foregoing, the Collateral Agent is hereby authorized to file one or more financing statements (including fixture filings), continuation statements, filings with the United States Patent and Trademark Office or United States Copyright Office (or any successor office or any similar office in any other country) or other documents for the purpose of perfecting, confirming, continuing, enforcing or protecting the Security Interest granted by each Grantor, without the signature of any Grantor, and naming any Grantor or the Grantors as debtors and the Collateral Agent as Secured Party.

(b) Notwithstanding anything to the contrary set forth in Section 2.01(a) above or the definition of the term "Collateral", Obligations of the Company or any US Subsidiary shall not be secured by more than 65% of the issued and outstanding voting Equity Interests of any Subsidiary that is not a US Subsidiary.

SECTION 2.02. <u>No Assumption of Liability.</u> The Security Interest is granted as security only and shall not subject the Collateral Agent or any other Secured Party to, or in any way alter or modify, any obligation or liability of any Grantor with respect to or arising out of the Collateral.

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

ARTICLE III

Representations and Warranties

The Grantors jointly and severally represent and warrant to the Collateral Agent and the Secured Parties that:

SECTION 3.01. <u>Title and Authority</u>. Each Grantor has good and valid rights in and title to the Collateral with respect to which it has purported to grant a Security Interest hereunder and has full power and authority to grant to the Collateral Agent the Security Interest in such Collateral pursuant hereto and to execute, deliver and perform its obligations in accordance with the terms of this Agreement, without the consent or approval of any other person other than any consent or approval which has been obtained or where the failure to obtain such consent would not materially impair the rights, remedies or benefits of the Secured Parties under the Security Interest purported to be granted hereunder.

SECTION 3.02. Filings. (a) The Perfection Certificate has been duly prepared, completed and executed and the information set forth therein is correct and complete in all material aspects. Fully executed Uniform Commercial Code financing statements (including fixture filings, as applicable) or other appropriate filings, recordings or registrations containing a description of the Collateral have been delivered to the Collateral Agent for filing in each governmental, municipal or other office specified in Schedule 6 to the Perfection Certificate, which are all the filings, recordings and registrations that are necessary to publish notice of and protect the validity of and to establish a legal, valid and perfected security interest in favor of the Collateral Agent (for the ratable benefit of the Secured Parties) in respect of all Collateral in which the Security Interest may be perfected by filing, recording or registration in the United States (or any political subdivision thereof) and its territories and possessions, and no further or subsequent filing, refiling, recording, rerecording, registration or reregistration is necessary in any such jurisdiction, except as provided under applicable law with respect to the filing of continuation statements or amendments reflecting the change of any Grantor's name or jurisdiction of organization.

(b) Each Grantor represents and warrants that fully executed security agreements in the form hereof or in a form similar thereto suitable for filing in the United States Patent and Trademark Office and the United States Copyright Office and containing a description of all Collateral consisting of registered and applied for Intellectual Property required to be set forth in Schedule II hereto have been delivered to the Collateral Agent for recording by the United States Patent and Trademark Office and the United States Copyright Office, as applicable, and otherwise as may be required pursuant to the laws of any other necessary jurisdiction, to protect the validity of and to establish a legal, valid and perfected security interest in favor of the Collateral Agent (for the ratable benefit of the Secured Parties) in respect of all such Collateral, and, other than the filing of Uniform Commercial Code financing statements indicated in Section 3.02(a), no further or subsequent filing, refiling, recording, rerecording, registration or reregistration is necessary (other than such actions as are necessary to perfect the Security Interest with respect to any Collateral consisting of registered Patents, Trademarks and Copyrights (or registration or application for registration thereof) acquired or developed after the date hereof).

SECTION 3.03. <u>Validity of Security Interest</u>. The Security Interest constitutes (a) a legal and valid security interest in all the Collateral securing the payment and performance of the Obligations and (b) a perfected security interest in all Collateral in which a security interest may be perfected by filing, recording or registering a financing statement or analogous document in the United States (or any political subdivision thereof) and its territories and possessions pursuant to the Uniform Commercial Code or other applicable law in such jurisdictions. The Security Interest is and shall be prior to any other Lien on any of the Collateral, other than Liens expressly permitted pursuant to Section 6.02 of the Credit Agreement.

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

SECTION 3.04. Absence of Other Liens. The Collateral is owned by the Grantors free and clear of any Lien, except for Liens expressly permitted pursuant to Section 6.02 of the Credit Agreement. No Grantor has filed or consented to the filing of (a) any financing statement or analogous document under the Uniform Commercial Code or any other applicable laws covering any Collateral, (b) any assignment in which any Grantor assigns any Collateral or any security agreement or similar instrument covering any Collateral with the United States Patent and Trademark Office or the United States Copyright Office or (c) any assignment in which any Grantor assigns any Collateral or any security agreement or similar instrument covering any Collateral with any foreign governmental, municipal or other office, which financing statement or analogous document, assignment, security agreement or similar instrument is still in effect, except, in each case, for Liens expressly permitted pursuant to Section 6.02 of the Credit Agreement.

SECTION 3.05 <u>Intellectual Property.</u> (a) On the date hereof, all material Intellectual Property is valid, subsisting, unexpired and enforceable, has not been abandoned and does not infringe the intellectual property rights of any other person except as would not result in a Material Adverse Effect.

- (b) None of the material Intellectual Property is the subject of any licensing or franchise agreement pursuant to which such Grantor is the licensor or franchisor.
- (c) No holding decision or judgment has been rendered by any Governmental Authority which would limit, cancel or question the validity of, or such Grantor's rights in, any Intellectual Property in any respect that could reasonably be expected to have a Material Adverse Effect.
- (d) No action or proceeding is pending, or, to the knowledge of such Grantor, threatened, on the date hereof (i) seeking to limit, cancel or question the validity of any Intellectual Property or such Grantor's ownership interest therein, or (ii) which, if adversely determined, would have a material adverse effect on the value of any Intellectual Property.
- (e) All Collateral consisting of Intellectual Property that is material to the business of the Company and the Subsidiaries is set forth in Schedule II hereto. At the time any additional Intellectual Property that is material to the business of the Company and the Subsidiaries shall become part of the Collateral, the Grantors shall deliver to the Collateral Agent a revised Schedule II setting forth all such Intellectual Property and all such Intellectual Property set forth in an earlier version of such Schedule II, which shall supersede all Schedules previously delivered pursuant to the requirements of this paragraph.

ARTICLE IV

Covenants

Business. (a) Each Grantor agrees promptly to notify the Collateral Agent in writing of any change (i) in the jurisdiction in which it is organized, (ii) in its name, (iii) in the location of its chief executive office, its principal place of business, or any office or facility at which Collateral owned by it is located (including the establishment of any such new office or facility), (iv) in its identity or corporate structure or (v) in its Federal Taxpayer Identification Number. Each Grantor agrees within 30 days of the occurrence of any change referred to in the preceding sentence to make all filings under the Uniform Commercial Code or otherwise that are required in order for the Collateral Agent to continue at all times following such change to have a valid, legal and perfected first priority security interest in all the Collateral. The Grantors agree promptly to notify the Collateral Agent if any material portion of the Collateral is damaged or destroyed.

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

(b) Each Grantor agrees to maintain, at its own cost and expense, such complete and accurate records with respect to the Collateral owned by it as is consistent with its current practices and in accordance with such prudent and standard practices used in industries that are the same as or similar to those in which such Grantor is engaged, but in any event to include complete accounting records indicating all payments and proceeds received with respect to any part of the Collateral, and, at such time or times as the Collateral Agent may reasonably request, promptly to prepare and deliver to the Collateral Agent a duly certified schedule or schedules in form and detail satisfactory to the Collateral Agent (which the Collateral Agent shall provide to any Secured Party at the reasonable request thereof) showing the identity, amount and location of any and all Collateral.

SECTION 4.02. <u>Protection of Security.</u> Each Grantor shall, at its own cost and expense, take any and all actions necessary to defend title to the Collateral against all persons and to defend the Security Interest of the Collateral Agent in the Collateral and the priority thereof against any Lien not expressly permitted pursuant to Section 6.02 of the Credit Agreement and which has a material adverse effect on the value of the Collateral.

SECTION 4.03. <u>Further Assurances.</u> (a) Each Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further instruments and documents and take all such actions as the Collateral Agent may from time to time reasonably request to better assure, preserve, protect and perfect the Security Interest and the rights and remedies created hereby, including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the Security Interest and the filing of any financing statements (including fixture filings) or other documents in connection herewith or therewith. If any amount payable to any Grantor under or in connection with any of the Collateral shall be or become evidenced by any promissory note or other instrument, such note or instrument shall be immediately pledged and delivered to the Collateral Agent, duly endorsed in a manner satisfactory to the Collateral Agent.

- (b) Without limiting the generality of the foregoing, each Grantor hereby authorizes the Collateral Agent, with prompt notice thereof to the Grantors, to supplement this Agreement by adding additional schedules hereto to specifically identify any asset or item that may constitute Collateral; provided, however, that any Grantor shall have the right, exercisable within 10 days after it has been notified by the Collateral Agent of the specific identification of such Collateral, to advise the Collateral Agent in writing of any inaccuracy of the representations and warranties made by such Grantor hereunder with respect to such Collateral. Each Grantor agrees that it will use its reasonable best efforts to take such action as shall be necessary in order that all representations and warranties hereunder shall be true and correct with respect to such Collateral within 30 days after the date it has been notified by the Collateral Agent of the specific identification of such Collateral.
- (c) For each deposit account that any Grantor at any time opens or maintains, such Grantor shall, at the Collateral Agent's request and option at any time after the occurrence of an Event of Default, pursuant to an agreement in form and substance satisfactory to the Collateral Agent, either (i) cause the depositary bank to agree to comply at any time with instructions from the Collateral Agent to such depositary bank directing the disposition of funds from time to time credited to such deposit account, without further consent of such Grantor, or (ii) arrange for the Collateral Agent to become the customer of the depositary bank with respect to the deposit account, with the Grantor being permitted, only with the consent of the Collateral Agent, to exercise rights to withdraw funds from such deposit account. The provisions of this paragraph shall not apply to deposit accounts for which the Collateral Agent is the depositary.
- (d) If any Grantor shall at any time hold or acquire a commercial tort claim with a value in excess of \$1,000,000, the Grantor shall immediately notify the Collateral Agent thereof in a writing signed by such Grantor including a summary description of such claim and grant to the Collateral Agent in such writing a security interest therein and in the proceeds thereof, all upon the

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

terms of this Agreement, with such writing to be in form and substance satisfactory to the Collateral Agent.

SECTION 4.04. <u>Inspection and Verification</u>. The Collateral Agent and such persons as the Collateral Agent may reasonably designate shall have the right, upon reasonable notice and at reasonable times (at the Grantors' own cost and expense for the first inspection in any calendar year only), to inspect the Collateral, all records related thereto (and to make extracts and copies from such records) and the premises upon which any of the Collateral is located, to discuss the Grantors' affairs with the officers of the Grantors and their independent accountants and to verify under reasonable procedures, in accordance with Section 5.09 of the Credit Agreement, the validity, amount, quality, quantity, value, condition and status of, or any other matter relating to, the Collateral, including, in the case of Accounts or Collateral in the possession of any third person, by contacting Account Debtors or the third person possessing such Collateral with the consent of the Company (such consent not to be unreasonably withheld or delayed) unless an Event of Default shall be continuing, in which case no consent of the Company shall be required, for the purpose of making such a verification. The Collateral Agent shall have the absolute right to share any information it gains from such inspection or verification with any Secured Party and shall provide such information to any Secured Party at the reasonable request thereof.

SECTION 4.05. <u>Taxes</u>; <u>Encumbrances</u>. At its option and after notice pursuant to Section 7.01, the Collateral Agent may discharge past due taxes, assessments, charges, fees, Liens, security interests or other encumbrances at any time levied or placed on the Collateral and not permitted pursuant to Section 6.02 of the Credit Agreement, and may pay for the maintenance and preservation of the Collateral to the extent any Grantor fails to do so as required by the Credit Agreement or this Agreement, and each Grantor jointly and severally agrees to reimburse the Collateral Agent on demand for any payment made or any expense incurred by the Collateral Agent pursuant to the foregoing authorization; <u>provided</u>, <u>however</u>, that nothing in this Section 4.05 shall be interpreted as excusing any Grantor from the performance of, or imposing any obligation on the Collateral Agent or any Secured Party to cure or perform, any covenants or other promises of any Grantor with respect to taxes, assessments, charges, fees, liens, security interests or other encumbrances and maintenance as set forth herein or in the other Loan Documents.

SECTION 4.06. Assignment of Security Interest. If at any time any Grantor shall take a security interest in any property of an Account Debtor or any other person to secure payment and performance of an Account, such Grantor shall promptly assign such security interest to the Collateral Agent. Such assignment need not be filed of public record unless the obligation secured by the assigned security interest is greater than \$20,000 and such filing is necessary to continue the perfected status of the security interest against creditors of and transferees from the Account Debtor or other person granting the security interest.

SECTION 4.07. <u>Continuing Obligations of the Grantors.</u> Each Grantor shall remain liable to observe and perform all the conditions and obligations to be observed and performed by it under each contract, agreement or instrument relating to the Collateral, all in accordance with the terms and conditions thereof, and each Grantor jointly and severally agrees to indemnify and hold harmless the Collateral Agent and the Secured Parties from and against any and all liability for such performance.

SECTION 4.08. <u>Use and Disposition of Collateral.</u> None of the Grantors shall make or permit to be made an assignment, pledge or hypothecation of the Collateral or shall grant any other Lien in respect of the Collateral, except as expressly permitted by Section 6.02 of the Credit Agreement. None of the Grantors shall make or permit to be made any transfer of the Collateral and each Grantor shall remain at all times in possession of the Collateral owned by it, except that (a) Inventory may be sold in the ordinary course of business and (b) unless and until the Collateral Agent shall notify the Grantors that an Event of Default shall have occurred and be continuing and that during the continuance thereof the Grantors shall not sell, convey, lease, assign, transfer or otherwise dispose of any Collateral (which notice may be given by telephone if

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

promptly confirmed in writing), the Grantors may use and dispose of the Collateral in any lawful manner not inconsistent with the provisions of this Agreement, the Credit Agreement or any other Loan Document. Without limiting the generality of the foregoing, each Grantor agrees that it shall not permit any Inventory with an aggregate fair market value in excess of \$100,000 to be in the possession or control of any warehouseman, bailee, agent or processor at any time unless such warehouseman, bailee, agent or processor shall have been notified of the Security Interest and shall have agreed in writing to hold the Inventory subject to the Security Interest and the instructions of the Collateral Agent and to waive and release any Lien held by it with respect to such Inventory, whether arising by operation of law or otherwise.

SECTION 4.09. <u>Limitation on Modification of Accounts</u>. None of the Grantors will, without the Collateral Agent's prior written consent, grant any extension of the time of payment of any of the Accounts Receivable, compromise, compound or settle the same for less than the full amount thereof, release, wholly or partly, any person liable for the payment thereof or allow any credit or discount whatsoever thereon, other than extensions, credits, discounts, compromises or settlements granted or made in the ordinary course of business and consistent with its current practices and in accordance with such prudent and standard practices used in industries that are the same as or similar to those in which such Grantor is engaged.

SECTION 4.10. <u>Insurance.</u> (a) The Grantors, at their own expense, shall maintain or cause to be maintained insurance covering physical loss or damage to the Inventory and Equipment in accordance with Section 5.05 of the Credit Agreement.

- (b) Each Grantor irrevocably makes, constitutes and appoints the Collateral Agent (and all officers, employees or agents designated by the Collateral Agent) as such Grantor's true and lawful agent (and attorney-in-fact) for the purpose, during the continuance of an Event of Default, of making, settling and adjusting claims in respect of Collateral under policies of insurance, endorsing the name of such Grantor on any check, draft, instrument or other item of payment for the proceeds of such policies of insurance and for making all determinations and decisions with respect thereto. In the event that any Grantor at any time or times shall fail to obtain or maintain any of the policies of insurance required hereby or to pay any premium in whole or part relating thereto, the Collateral Agent may, without waiving or releasing any obligation or liability of the Grantors hereunder or any Event of Default, in its sole discretion, obtain and maintain such policies of insurance and pay such premium and take any other actions with respect thereto as the Collateral Agent deems advisable. All sums disbursed by the Collateral Agent in connection with this Section 4.10, including reasonable attorneys' fees, court costs, expenses and other charges relating thereto, shall be payable, upon demand, by the Grantors to the Collateral Agent and shall be additional Obligations secured hereby.
- (c) Each Grantor agrees to cause all insurance policies related to the insurance described in clause (a) of this Section 4.10 to be endorsed or otherwise amended to include a lender's loss payable endorsement, in form and substance reasonably satisfactory to the Collateral Agent.
- SECTION 4.11. <u>Legend.</u> Each Grantor shall legend, in form and manner satisfactory to the Collateral Agent, its books, records and documents evidencing or pertaining to Accounts Receivable with an appropriate reference to the fact that such Accounts Receivable have been assigned to the Collateral Agent for the benefit of the Secured Parties and that the Collateral Agent has a security interest therein.
- SECTION 4.12. <u>Intellectual Property.</u> (a) Each Grantor agrees that it will not, nor will it permit any of its licensees to, do any act, or omit to do any act, whereby any Patent which is material to the conduct of such Grantor's business may become invalidated or dedicated to the public, and agrees that it shall continue to mark any products covered by a Patent with the relevant patent number as necessary and sufficient to establish and preserve its maximum rights under applicable patent laws.

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

- (b) Each Grantor (either itself or through its licensees or its sublicensees) will, for each Trademark material to the conduct of such Grantor's business, (i) maintain such Trademark in full force free from any claim of abandonment or invalidity for non-use, (ii) maintain the quality of products and services offered under such Trademark, (iii) display such Trademark with notice of Federal or foreign registration, if any, to the extent necessary and sufficient to establish and preserve its maximum rights under applicable law and (iv) not knowingly use or knowingly permit the use of such Trademark in violation of any third party rights.
- (c) Each Grantor (either itself or through licensees) will, for each work covered by a material Copyright, continue to publish, reproduce, display, adopt and distribute the work with appropriate copyright notice as necessary and sufficient to establish and preserve its maximum rights under applicable copyright laws.
- (d) Each Grantor shall notify the Collateral Agent immediately if it knows or has reason to know that any Patent, Trademark or Copyright material to the conduct of its business may become abandoned, lost or dedicated to the public, or of any adverse determination or development (including the institution of, or any such determination or development in, any proceeding in the United States Patent and Trademark Office, United States Copyright Office or any court or similar office of any country) regarding such Grantor's ownership of any Patent, Trademark or Copyright, its right to register the same, or to keep and maintain the same.
- (e) In no event shall any Grantor, either itself or through any agent, employee, licensee or designee, file an application for any Patent, Trademark or Copyright (or for the registration of any Trademark or Copyright) with the United States Patent and Trademark Office, United States Copyright Office or any office or agency in any political subdivision of the United States or in any other country or any political subdivision thereof, unless it promptly informs the Collateral Agent, and, upon request of the Collateral Agent, executes and delivers any and all agreements, instruments, documents and papers as the Collateral Agent may request to evidence the Collateral Agent's security interest in such Patent, Trademark or Copyright, and each Grantor hereby appoints the Collateral Agent as its attorney-in-fact to execute and file such writings to evidence the Collateral Agent's security interest, all acts of such attorney being hereby ratified and confirmed; such power, being coupled with an interest, is irrevocable.
- (f) Each Grantor will take all necessary steps that are consistent with the practice in any proceeding before the United States Patent and Trademark Office, United States Copyright Office or any office or agency in any political subdivision of the United States or in any other country or any political subdivision thereof, to maintain and pursue each material application relating to the Patents, Trademarks and/or Copyrights (and to obtain the relevant grant or registration) and to maintain each issued Patent and each registration of the Trademarks and Copyrights that is material to the conduct of any Grantor's business, including timely filings of applications for renewal, affidavits of use, affidavits of incontestability and payment of maintenance fees, and, if consistent with good business judgment, to initiate opposition, interference and cancellation proceedings against third parties.
- (g) In the event that any Grantor has reason to believe that any Collateral consisting of a Patent, Trademark or Copyright material to the conduct of any Grantor's business has been or is about to be infringed, misappropriated or diluted by a third party, such Grantor promptly shall notify the Collateral Agent and shall, if consistent with good business judgment, promptly sue for infringement, misappropriation or dilution and to recover any and all damages for such infringement, misappropriation or dilution, and take such other actions as are appropriate under the circumstances to protect such Collateral.
- (h) Upon and during the continuance of an Event of Default, each Grantor shall use its reasonable best efforts to obtain all requisite consents or approvals by the licensor of each Copyright License, Patent License or Trademark License to effect the assignment provided for in

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

Section 6.01 of all of such Grantor's right, title and interest thereunder to the Collateral Agent or its designee.

SECTION 4.13. Federal Assignment of Claims Act. Each Grantor agrees that, at the request of the Collateral Agent, following the occurrence and during the continuance of an Event of Default, such Grantor will execute any and all documents, notices or instruments as may be necessary or desirable, or as the Agent may reasonably request, to direct, and enable the Collateral Agent to cause, the United States government to pay to the Collateral Agent, for the account of the Secured Parties, all amounts otherwise payable to the Grantors under the Assignment of Claims Act, 31 U.S.C. § 3727 and 41 U.S.C. § 15.

ARTICLE V

Power of Attorney

SECTION 5.01. Power of Attorney. Each Grantor irrevocably makes, constitutes and appoints the Collateral Agent (and all officers, employees or agents designated by the Collateral Agent) as such Grantor's true and lawful agent and attorney-in-fact, and in such capacity the Collateral Agent shall have the right, with power of substitution for each Grantor and in each Grantor's name or otherwise, for the use and benefit of the Collateral Agent and the Secured Parties, upon the occurrence and during the continuance of an Event of Default (a) to receive, endorse, assign and/or deliver any and all notes, acceptances, checks, drafts, money orders or other evidences of payment relating to the Collateral or any part thereof; (b) to demand, collect, receive payment of, give receipt for and give discharges and releases of all or any of the Collateral; (c) to sign the name of any Grantor on any invoice or bill of lading relating to any of the Collateral; (d) to send verifications of Accounts Receivable to any Account Debtor; (e) to commence and prosecute any and all suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect or otherwise realize on all or any of the Collateral or to enforce any rights in respect of any Collateral; (f) to settle, compromise, compound, adjust or defend any actions, suits or proceedings relating to all or any of the Collateral; (g) to notify, or to require any Grantor to notify, Account Debtors to make payment directly to the Collateral Agent; and (h) to use, sell, assign, transfer, pledge, make any agreement with respect to or otherwise deal with all or any of the Collateral, and to do all other acts and things necessary to carry out the purposes of this Agreement, as fully and completely as though the Collateral Agent were the absolute owner of the Collateral for all purposes; provided, however, that nothing herein contained shall be construed as requiring or obligating the Collateral Agent or any Secured Party to make any commitment or to make any inquiry as to the nature or sufficiency of any payment received by the Collateral Agent or any Secured Party, or to present or file any claim or notice, or to take any action with respect to the Collateral or any part thereof or the moneys due or to become due in respect thereof or any property covered thereby, and no action taken or omitted to be taken by the Collateral Agent or any Secured Party with respect to the Collateral or any part thereof shall give rise to any defense, counterclaim or offset in favor of any Grantor or to any claim or action against the Collateral Agent or any Secured Party. It is understood and agreed that the appointment of the Collateral Agent as the agent and attorney-in-fact of the Grantors for the purposes set forth above is coupled with an interest and is irrevocable. The provisions of this Section shall in no event relieve any Grantor of any of its obligations hereunder or under any other Loan Document with respect to the Collateral or any part thereof or impose any obligation on the Collateral Agent or any Secured Party to proceed in any particular manner with respect to the Collateral or any part thereof, or in any way limit the exercise by the Collateral Agent or any Secured Party of any other or further right which it may have on the date of this Agreement or hereafter, whether hereunder, under any other Loan Document, by law or otherwise.

ARTICLE VI

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

Remedies

SECTION 6.01. Remedies upon Default. Upon the occurrence and during the continuance of an Event of Default, each Grantor agrees to assemble the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place to be designated by the Collateral Agent reasonably convenient to all parties, and it is agreed that the Collateral Agent shall have the right to take any of or all the following actions at the same or different times (subject to the notice provisions below): (a) with respect to any Collateral consisting of Intellectual Property, on demand, to cause the Security Interest to become an assignment, transfer and conveyance of any of or all such Collateral by the applicable Grantors to the Collateral Agent or to license or sublicense, whether general, special or otherwise, and whether on an exclusive or nonexclusive basis, any such Collateral throughout the world on such terms and conditions and in such manner as the Collateral Agent shall determine (other than in violation of any then-existing licensing arrangements to the extent that waivers cannot be obtained) and (b) with or without legal process and with or without prior notice or demand for performance, to take possession of the Collateral and without liability for trespass to enter any premises where the Collateral may be located for the purpose of taking possession of or removing the Collateral, exercise any Grantor's right to bill and receive payment for completed work, and, generally, to exercise any and all rights afforded to a Secured Party under the Uniform Commercial Code or other applicable law. Without limiting the generality of the foregoing, each Grantor agrees that the Collateral Agent shall have the right, subject to the mandatory requirements of applicable law, to sell or otherwise dispose of all or any part of the Collateral, at public or private sale or at any broker's board or on any securities exchange, for cash, upon credit or for future delivery as the Collateral Agent shall deem appropriate. The Collateral Agent shall be authorized at any such sale (if it deems it advisable to do so) to restrict the prospective bidders or purchasers to persons who will represent and agree that they are purchasing any Collateral which constitutes a "security" under applicable securities law for their own account for investment and not with a view to the distribution or sale thereof, and upon consummation of any such sale the Collateral Agent shall have the right to assign, transfer and deliver to the purchaser or purchasers thereof the Collateral so sold. Each such purchaser at any such sale shall hold the property sold absolutely, free from any claim or right on the part of any Grantor, and each Grantor hereby waives (to the extent permitted by law) all rights of redemption, stay and appraisal which such Grantor now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted.

The Collateral Agent shall give the Grantors 10 days' written notice (which each Grantor agrees is reasonable notice within the meaning of Section 9-612 of the Uniform Commercial Code as in effect in the State of New York or its equivalent in other jurisdictions) of the Collateral Agent's intention to make any sale of Collateral. Such notice, in the case of a public sale, shall state the time and place for such sale and, in the case of a sale at a broker's board or on a securities exchange, shall state the board or exchange at which such sale is to be made and the day on which the Collateral, or portion thereof, will first be offered for sale at such board or exchange. Any such public sale shall be held at such time or times within ordinary business hours and at such place or places as the Collateral Agent may fix and state in the notice (if any) of such sale. At any such sale, the Collateral, or portion thereof, to be sold may be sold in one lot as an entirety or in separate parcels, as the Collateral Agent may (in its sole and absolute discretion) determine. The Collateral Agent shall not be obligated to make any sale of any Collateral if it shall determine not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. The Collateral Agent may, without notice or publication, adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed for sale, and such sale may, without further notice, be made at the time and place to which the same was so adjourned. In case any sale of all or any part of the Collateral is made on credit or for future delivery, the Collateral so sold may be retained by the Collateral Agent until the sale price is paid by the purchaser or purchasers thereof, but the Collateral Agent shall not incur any liability in case any such purchaser or purchasers shall fail to take up and pay for the Collateral so sold and, in case of any such failure, such Collateral may be sold again upon like notice. At any public (or, to the extent permitted by law, private) sale made pursuant to this Section, any Secured Party may

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

bid for or purchase, free (to the extent permitted by law) from any right of redemption, stay, valuation or appraisal on the part of any Grantor (all said rights being also hereby waived and released to the extent permitted by law), the Collateral or any part thereof offered for sale and may make payment on account thereof by using any claim then due and payable to such Secured Party from any Grantor as a credit against the purchase price, and such Secured Party may, upon compliance with the terms of sale, hold, retain and dispose of such property without further accountability to any Grantor therefor. For purposes hereof, a written agreement to purchase the Collateral or any portion thereof shall be treated as a sale thereof; the Collateral Agent shall be free to carry out such sale pursuant to such agreement and no Grantor shall be entitled to the return of the Collateral or any portion thereof subject thereto, notwithstanding the fact that after the Collateral Agent shall have entered into such an agreement all Events of Default shall have been remedied and the Obligations paid in full. As an alternative to exercising the power of sale herein conferred upon it, the Collateral Agent may proceed by a suit or suits at law or in equity to foreclose this Agreement and to sell the Collateral or any portion thereof pursuant to a judgment or decree of a court or courts having competent jurisdiction or pursuant to a proceeding by a courtappointed receiver. The Collateral Agent agrees that it will handle and care for any Collateral in its possession in a manner not inconsistent with that in which a reasonable person would handle and care for his or her own property.

SECTION 6.02. <u>Application of Proceeds</u>. The Collateral Agent shall apply the proceeds of any collection or sale of the Collateral, as well as any Collateral consisting of cash, as follows:

FIRST, to the payment of all reasonable costs and expenses incurred by the Administrative Agent or the Collateral Agent (in its capacity as such hereunder or under any other Loan Document) in connection with such collection or sale or otherwise in connection with this Agreement or any of the Obligations, including all court costs and the reasonable fees and expenses of its agents and legal counsel, the repayment of all advances made by the Collateral Agent hereunder or under any other Loan Document on behalf of any Grantor and any other costs or expenses incurred in connection with the exercise of any right or remedy hereunder or under any other Loan Document;

SECOND, to the payment in full of the Obligations (the amounts so applied to be distributed among the Secured Parties pro rata in accordance with the amounts of the Obligations owed to them on the date of any such distribution); and

THIRD, to the Grantors, their successors or assigns, or as a court of competent jurisdiction may otherwise direct.

The Collateral Agent shall have absolute discretion as to the time of application of any such proceeds, moneys or balances in accordance with this Agreement (it being agreed that the Collateral Agent will not exercise such discretion in a manner that is commercially unreasonable under the circumstances). Upon any sale of the Collateral by the Collateral Agent (including pursuant to a power of sale granted by statute or under a judicial proceeding), the receipt of the Collateral Agent or of the officer making the sale shall be a sufficient discharge to the purchaser or purchasers of the Collateral so sold and such purchaser or purchasers shall not be obligated to see to the application of any part of the purchase money paid over to the Collateral Agent or such officer or be answerable in any way for the misapplication thereof.

of enabling the Collateral Agent to exercise rights and remedies under this Article at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, each Grantor hereby grants to the Collateral Agent an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation to the Grantors) to use, license or sub-license any of the Collateral consisting of Intellectual Property now owned or hereafter acquired by such Grantor, Collateral consisting of Intellectual Property now owned or hereafter acquired by such Grantor, and wherever the same may be located, and including in such license reasonable access to all media

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof. The use of such license by the Collateral Agent may be exercised, at the option of the Collateral Agent, upon the occurrence and during the continuation of an Event of Default; <u>provided</u> that any license, sub-license or other transaction entered into by the Collateral Agent in accordance herewith shall be binding upon the Grantors notwithstanding any subsequent cure of an Event of Default.

ARTICLE VII

Miscellaneous

SECTION 7.01. <u>Notices.</u> All communications and notices hereunder shall (except as otherwise expressly permitted herein) be in writing and given as provided in Section 9.01 of the Credit Agreement. All communications and notices hereunder to any Grantor shall be given to it in care of the Company.

SECTION 7.02. Security Interest Absolute. All rights of the Collateral Agent hereunder, the Security Interest and all obligations of the Grantors hereunder shall be absolute and unconditional irrespective of (a) any lack of validity or enforceability of the Credit Agreement, any other Loan Document, any agreement with respect to any of the Obligations or any other agreement or instrument relating to any of the foregoing, (b) any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to any departure from the Credit Agreement, any other Loan Document or any other agreement or instrument, (c) any exchange, release or non-perfection of any Lien on other collateral, or any release or amendment or waiver of or consent under or departure from any guarantee, securing or guaranteeing all or any of the Obligations, or (d) any other circumstance that might otherwise constitute a defense available to, or a discharge of, any Grantor in respect of the Obligations or this Agreement (other than the indefeasible cash payment in full of all the Obligations).

SECTION 7.03. <u>Survival of Agreement.</u> All covenants, agreements, representations and warranties made by any Grantor herein and in the certificates or other instruments prepared or delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by the Secured Parties and shall survive the making by the Lenders of the Loans, and the execution and delivery to the Lenders of any notes evidencing such Loans, regardless of any investigation made by the Lenders or on their behalf, and shall continue in full force and effect until this Agreement shall terminate.

SECTION 7.04. <u>Binding Effect; Several Agreement.</u> This Agreement shall become effective as to any Grantor when a counterpart hereof executed on behalf of such Grantor shall have been delivered to the Collateral Agent and a counterpart hereof shall have been executed on behalf of the Collateral Agent, and thereafter this Agreement shall be binding upon such Grantor and the Collateral Agent and their respective successors and assigns and shall inure to the benefit of such Grantor, the Collateral Agent and the other Secured Parties and their respective successors and assigns, except that no Grantor shall have the right to assign or transfer its rights or obligations hereunder or any interest herein or in the Collateral (and any such assignment or transfer shall be void) except as expressly contemplated by this Agreement or the Credit Agreement. This Agreement shall be construed as a separate agreement with respect to each Grantor and may be amended, modified, supplemented, waived or released with respect to any Grantor without the approval of any other Grantor and without affecting the obligations of any other Grantor hereunder.

SECTION 7.05. <u>Successors and Assigns.</u> Whenever in this Agreement any of the parties hereto is referred to, such reference shall be deemed to include the successors and assigns of such party; and all covenants, promises and agreements by or on behalf of any Grantor or the

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

Collateral Agent that are contained in this Agreement shall bind and inure to the benefit of their respective successors and assigns.

- SECTION 7.06. Collateral Agent's Fees and Expenses; Indemnification.

 (a) Each Grantor jointly and severally agrees to pay upon demand to the Collateral Agent the amount of any and all reasonable expenses, including the reasonable fees, disbursements and other charges of its counsel and of any experts or agents, which the Collateral Agent may incur in connection with (i) the administration of this Agreement (including the customary fees and charges of the Collateral Agent for any audits conducted by it or on its behalf with respect to the Accounts Receivable or Inventory), (ii) the custody or preservation of, or the sale of, collection from or other realization upon any of the Collateral, (iii) the exercise, enforcement or protection of any of the rights of the Collateral Agent hereunder or (iv) the failure of any Grantor to perform or observe any of the provisions hereof.
- (b) Without limitation of its indemnification obligations under the other Loan Documents, each Grantor jointly and severally agrees to indemnify the Collateral Agent and the other indemnitees against, and hold each of them harmless from, any and all losses, claims, damages, liabilities and related expenses, including reasonable fees, disbursements and other charges of counsel, incurred by or asserted against any of them arising out of, in any way connected with, or as a result of, the execution, delivery or performance of this Agreement or any claim, litigation, investigation or proceeding relating hereto or to the Collateral, whether or not any indemnitee is a party thereto; provided that such indemnity shall not, as to any indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or wilful misconduct of such indemnitee.
- Obligations secured hereby and by the other Security Documents. The provisions of this Section 7.06 shall remain operative and in full force and effect regardless of the termination of this Agreement or any other Loan Document, the consummation of the transactions contemplated hereby, the repayment of any of the Obligations, the invalidity or unenforceability of any term or provision of this Agreement or any other Loan Document, or any investigation made by or on behalf of the Collateral Agent or any other Secured Party. All amounts due under this Section 7.06 shall be payable on written demand therefor and shall bear interest at the rate specified in Section 2.12 of the Credit Agreement.

SECTION 7.07. <u>GOVERNING LAW.</u> THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

Agent in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Collateral Agent hereunder and of the Collateral Agent, the Issuing Banks, the Administrative Agent and the Lenders under the other Loan Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provisions of this Agreement or any other Loan Document or consent to any departure by any Grantor therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) below, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand on any Grantor in any case shall entitle such Grantor or any other Grantor to any other or further notice or demand in similar or other circumstances.

(b) Neither this Agreement nor any provision hereof may be waived, amended or modified except (i) pursuant to an agreement or agreements in writing entered into by the Collateral

Agent and the Grantor or Grantors with respect to which such waiver, amendment or modification is to apply and (ii) subject to any consent required in accordance with Section 9.02 of the Credit Agreement.

SECTION 7.09. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 7.09.

SECTION 7.10. Severability. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 7.11 <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract (subject to Section 7.04), and shall become effective as provided in Section 7.04. Delivery of an executed signature page to this Agreement by facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.

SECTION 7.12. <u>Headings.</u> Article and Section headings used herein are for the purpose of reference only, are not part of this Agreement and are not to affect the construction of, or to be taken into consideration in interpreting, this Agreement.

SECTION 7.13. <u>Jurisdiction; Consent to Service of Process.</u> (a) Each Grantor hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or the other Loan Documents, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that the Collateral Agent, the Administrative Agent, any Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or the other Loan Documents against any Grantor or its properties in the courts of any jurisdiction.

(b) Each Grantor hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or the other Loan Documents in any New York State or Federal court. Each of the parties hereto hereby

irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

- (c) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 7.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law.
- SECTION 7.14. <u>Termination; Release of Collateral.</u> (a) This Agreement and the Security Interest shall terminate when all the Obligations (other than wholly contingent indemnification obligations) have been indefeasibly paid in full, the Lenders have no further commitment to lend, the LC Exposure has been reduced to zero and no Issuing Bank has any further commitment to issue Letters of Credit under the Credit Agreement, at which time the Collateral Agent shall execute and deliver to the Grantors, at the Grantors' expense, all Uniform Commercial Code termination statements, terminations and reassignments for mortgages and assignments of copyrights, patents and trademarks, and similar documents which the Grantors shall reasonably request to evidence such termination. Any execution and delivery of termination statements or documents pursuant to this Section 7.14 shall be without recourse to or warranty by the Collateral Agent.
- (b) The Collateral Agent shall release items of Collateral that shall be sold or otherwise disposed of in transactions permitted under the Credit Agreement on the terms and subject to the conditions and limitations set forth in Section 9.13 of the Credit Agreement.
- SECTION 7.15. Additional Grantors. Pursuant to Section 5.11 of the Credit Agreement, each US Subsidiary that was not in existence or was not a US Subsidiary on the date of the Credit Agreement is required to enter into this Agreement as a Grantor upon becoming such a US Subsidiary. Upon execution and delivery by the Collateral Agent and such a Subsidiary of a Supplement in the form of Annex 1 hereto, such Subsidiary shall become a Grantor hereunder with the same force and effect as if originally named as a Grantor herein. The execution and delivery of any such instrument shall not require the consent of any Grantor hereunder. The rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Agreement.

20

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

LABONE, INC.,

Name: John W. McCarty Fitle: EVP/CFO

EXAMONE WORLD WIDE, INC.,

Name: John W. McCarty Title: EVP/CFO

OSBORN GROUP, INC.,

Name: John W. McCarty Title: EVP/CFO

SYSTEMATIC BUSINESS SERVICES, INC.,

Name: John W. McCarty Ditle: EVP/CFO

JPMORGAN CHASE BANK, as Collateral Agent,

by

Name: Title:

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

LABONE, INC.,
by
Name: Title:
EXAMONE WORLD WIDE, INC.,
by
Name: Title:
OSBORN GROUP, INC.,
by
Name: Ti tle:
SYSTEMATIC BUSINESS SERVICES, INC
by
Name: Title:
JPMORGAN CHASE BANK, as Collateral Agent, by Collect Patterned Name: ROBERT BOTTAMED! VICE PRESIDENT

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

SCHEDULE I to SECURITY AGREEMENT

Subsidiary Grantors

ExamOne World Wide, Inc. Osborn Group, Inc. Systematic Business Services, Inc.

<<NYCORP-2093901.5:4412W:06/10/02-12:44p>>

INTELLECTUAL PROPERTY AND LICENSES OWNED BY [NAME OF GRANTOR]

[Make a separate Schedule II for each Grantor and if no Intellectual Property or License owned so state.]

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

SUPPLEMENT NO. dated as of to the SECURITY AGREEMENT dated as of June 11, 2002 (the "Security Agreement"), among LABONE, INC., a Missouri corporation (the "Company"), each Subsidiary of the Company listed on Schedule I thereto or becoming a party thereto as provided in Section 7.15 thereof (the "Subsidiary Guarantors", the Company and the Subsidiary Grantors being referred to collectively as the "Grantors") and JPMORGAN CHASE BANK, a New York banking corporation, as collateral agent (in such capacity, the "Collateral Agent") for the Secured Parties (as defined in the Credit Agreement referred to below).

- A. Reference is made to (A) the Credit Agreement dated as of June 11, 2002 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Company, the lenders from time to time party thereto (the "Lenders"), the issuing banks from time to time thereto (the "Issuing Banks"), and JPMorgan Chase Bank, as administrative agent (in such capacity, the "Administrative Agent") and as Collateral Agent and (b) the Security Documents and other Loan Documents referred to in the Credit Agreement.
- B. Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Security Agreement and the Credit Agreement.
- C. The Grantors have entered into the Security Agreement in order to induce the Lenders and Issuing Banks to extend credit to the Company. Section 7.15 of the Security Agreement provides that additional Subsidiaries may become Grantors under the Security Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Subsidiary (the "New Grantor") is executing this Supplement in accordance with the requirements of the Credit Agreement to become a Grantor under the Security Agreement in order to induce the Lenders and Issuing Banks to extend credit and as consideration for credit previously extended.

Accordingly, the Collateral Agent and the New Grantor agree as follows:

SECTION 1. In accordance with Section 7.15 of the Security Agreement, the New Grantor by its signature below becomes a Grantor under the Security Agreement with the same force and effect as if originally named therein as a Grantor and the New Grantor hereby (a) agrees to all the terms and provisions of the Security Agreement applicable to it as a Grantor thereunder and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct on and as of the date hereof. In furtherance of the foregoing, the New Grantor, as security for the payment and performance in full of the Obligations (as defined in the Credit Agreement), does hereby create and grant to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, their successors and assigns, a security interest in and lien on all of the New Grantor's right, title and interest in and to the Collateral (as defined in the Security Agreement) of the New Grantor. Each reference to a "Grantor" in the Security Agreement shall be deemed to include the New Grantor. The Security Agreement is hereby incorporated herein by reference.

SECTION 2. The New Grantor represents and warrants to the Collateral Agent and the other Secured Parties that this Supplement has been duly authorized, executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms.

SECTION 3. This Supplement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Supplement shall become effective when the Collateral Agent shall have received counterparts of this Supplement that, when taken together, bear the signatures of the New Grantor and the Collateral Agent. Delivery of an executed signature page to this Supplement by taken transmission shall be as effective as delivery of a manually signed counterpart of this Supplement.

SECTION 4. The New Grantor hereby represents and warrants that (a) set forth on Schedule I attached hereto is a true and correct schedule of the location of any and all Collateral of the New

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

Grantor and (b) set forth under on Schedule II hereto, is the true and correct location of the chief executive office of the New Grantor and the jurisdiction of organization of the New Grantor.

SECTION 5. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect.

SECTION 6. THIS SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

SECTION 7. In case any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Security Agreement shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 8. All communications and notices hereunder shall be in writing and given as provided in Section 7.01 of the Security Agreement. All communications and notices hereunder to the New Grantor shall be given to it in care of the Company.

SECTION 9. The New Grantor agrees to reimburse the Collateral Agent for its reasonable out-of-pocket expenses in connection with this Supplement, including the reasonable fees, other charges and disbursements of counsel for the Collateral Agent.

<<NYCORP~2093901.5;4412W:06/10/02-12:44p>>

IN WITNESS WHEREOF, the New Grantor and the Collateral Agent have duly executed this Supplement to the Security Agreement as of the day and year first above written.

[Name of New Grantor],
by
Name: Title:
JPMORGAN CHASE BANK, as Collateral Agent,
by
Name:
Title:

LOCATION OF COLLATERAL

Description

Location

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>

NEW GRANTORS

Name Address

Jurisdiction of Organization

<<NYCORP~2093901.5:4412W:06/10/02-12:44p>>